



Artificial Intelligence in Personalized Breast Cancer Medicine: Current Trends and Future Directions

Saeede Zibaei^{1*}, Mohadeseh Sadeghinia¹

¹Biology Department, Shahab-Danesh University, Qom, Iran.

Corresponding Author's E-mail : saeedezibaei7887@gmail.com.

Abstract:

Breast cancer is one of the most common types of cancer among women. This disease poses serious clinical challenges due to its variable response to treatment and biological heterogeneity. Therefore, conventional therapies fail to complement the characteristics of specific tumors, limiting the effectiveness of treatment even in personalized therapies. In recent years, powerful tools such as artificial intelligence (AI), have emerged to advance personalized medicine, especially in the field of breast cancer, with the help of which complex biomedical data can be better analyzed.

In this article, we aim to provide a comprehensive review of the impact of AI on early detection, prognosis and recurrence assessment, response prediction, biomarker discovery, and clinical decision-making in breast cancer. We will also explore how AI-based imaging analysis can help improve diagnostic accuracy, while integrated multi-omics models can enhance treatment decision-making and risk stratification. Emerging approaches such as explainable AI, radiogenomics, and AI-based multi-omics integration are also highlighted as key drivers in this field.

Despite encouraging results, significant challenges remain, including data heterogeneity, limited external and prospective validation, algorithmic bias, interpretability concerns, and ethical and regulatory barriers. Addressing these limitations through standardized data protocols, transparent and explainable models, and multi-center validation studies is essential for safe and equitable implementation. Overall, AI holds substantial potential to transform breast cancer management toward a more predictive, preventive, and patient-centered paradigm, provided that technological innovation is aligned with robust clinical validation and interdisciplinary collaboration.

Keywords: Artificial Intelligence, Breast Cancer, Personalized Medicine, Machine Learning, Multi-omics Integration.

INTRODUCTION

It is perhaps safe to say that breast cancer is one of the most common cancers in women, and it has emerged as one of the leading causes of death in the world (8, 61). Despite extensive advances in treatment, early detection, and clinical pathways,

the biological heterogeneity of breast tumors has made traditional clinical pathways unable to provide an appropriate therapeutic response for individuals (3, 23). Precision medicine seeks to overcome these limitations by tailoring medical care based on patient-specific clinical, imaging, and

COPYRIGHTS

The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article:

S. Zibaei, M. Sadeghinia "Artificial Intelligence in Personalized Breast Cancer Medicine: Current Trends and Future Directions", Advanced Therapies Journal, vol. 8, no. 26, pp. 1-15, 2026.

molecular profiles (2, 62). However, the analysis of high-dimensional biomedical datasets poses significant challenges for conventional statistical methods due to scale, complexity, and non-linear relationships (16, 21). Artificial intelligence (AI), driven by advancements in machine learning and deep learning, has recently become a pivotal tool in oncology for deciphering complex data patterns and aiding clinical decision-making (1, 5). Comparative studies demonstrate that AI models surpass conventional methods in medical imaging by enhancing diagnostic sensitivity and specificity, refining risk stratification, and offering superior accuracy in predicting therapeutic outcomes (4, 58). Nevertheless, the seamless integration of AI into daily clinical workflows is hindered by challenges such as model opacity (lack of interpretability), the need for standardized data, and the necessity for rigorous external validation (10, 29). Consequently, a thorough examination of AI's role in precision breast cancer medicine is crucial to understanding how these innovations can be effectively translated into patient care. In the realm of breast cancer management, AI has shown immense potential in improving early detection, prognostic assessment, and tailored treatment planning (22, 66). Specifically, AI-driven algorithms have demonstrated superior performance over standard interpretative techniques in mammography and MRI, facilitating more consistent and precise tumor identification (32, 67). Beyond imaging, the application of AI in synthesizing multi-omics data has facilitated the identification of novel biomarkers and significantly improved predictive models for treatment efficacy and disease recurrence (13, 35). For instance, systematic reviews report that AI-based recurrence prediction models, trained on clinical and imaging cohorts, can stratify patients by risk with higher precision than conventional approaches. Furthermore, explainable AI methods are gaining attention for improving model transparency and clinical trust, which are crucial for adoption in precision oncology (18, 60). Despite the potential benefits, the broad adoption of AI-driven personalized medicine faces significant hurdles, including ethical dilemmas, data heterogeneity, and the requirement for extensive, annotated datasets (53, 29).

Epidemiology and Clinical Challenges of Breast Cancer

Globally, breast cancer continues to be the leading cause of cancer diagnosis among women, and its prevalence is increasing in many areas despite sustained public health initiatives (61). According to recent global estimates, breast cancer accounts for millions of new cases annually, with substantial geographic variation in rates due to differences in screening practices, lifestyle factors, and healthcare

access (8). High-income countries often report higher age-standardized incidence rates, reflecting broad screening and early detection, whereas low- and middle-income regions bear disproportionately high mortality relative to incidence, highlighting disparities in care (8, 61). Risk factors for breast cancer encompass both non-modifiable elements such as age and genetic predisposition, and modifiable influences including obesity, alcohol consumption, and physical inactivity (3, 12). Moreover, epidemiological trends show an increasing burden of breast cancer among younger women and diverse populations, complicating traditional risk stratification and screening frameworks (66). The clinical phenotype is inherently linked to the underlying molecular subtype of the tumor. Notably, aggressive variants such as triple-negative breast cancer impose significant therapeutic difficulties, primarily due to the lack of viable targeted treatment strategies. These trends underscore the dynamic epidemiology of the disease and the need for adaptive clinical strategies that address both prevention and personalized treatment access. Consequently, understanding population-level patterns and underlying determinants of breast cancer remains foundational for advancing precision oncology. Despite improvements in early detection and therapeutic advances over recent decades, breast cancer continues to present significant clinical challenges that hinder optimal outcomes (11, 23). A pivotal challenge lies in the substantial heterogeneity of breast cancer, both molecularly and clinically. The disease encompasses distinct molecular entities, notably hormone receptor-positive (HR+), HER2-positive, and triple-negative subtypes, which display diverse growth dynamics, varying responses to therapeutic interventions, and differing prognostic outcomes (12, 31). This biological diversity complicates one-size-fits-all treatment paradigms and underscores the need for tailored approaches that integrate molecular profiling into clinical decision-making. Furthermore, disparities in healthcare infrastructure and resource availability contribute to delayed diagnoses and limited treatment options in many regions, exacerbating mortality rates and inequities in survival (11, 61). Even within high-resource settings, clinical challenges persist, including the management of advanced and metastatic disease, treatment resistance, and the balance between therapeutic efficacy and quality of life. Psychological, social, and economic burdens also add layers of complexity to patient care, requiring multidisciplinary support beyond conventional medical interventions. Addressing these multifaceted challenges necessitates an integrated approach that combines better epidemiologic insights, personalized treatment frameworks, and equitable healthcare delivery systems worldwide.

Principles of Personalized Medicine in Oncology Precision oncology marks a significant departure from conventional ‘one-size-fits-all’ strategies, adopting a framework that customizes diagnostic and therapeutic interventions according to the unique genetic, molecular, and environmental profile of each patient (62, 28). At its foundation, this approach synthesizes genomic profiling, biomarker discovery, and targeted treatments to align specific tumor characteristics with the most appropriate clinical management plans (12, 35). The advent of advanced technologies, such as next-generation sequencing (NGS) and liquid biopsies, has revolutionized the analysis of tumor DNA by offering rapid, economical, and clinically actionable data (31, 13). These tools empower clinicians to detect driver mutations, stratify patients based on risk levels, and prescribe therapies with a higher probability of success for specific molecular subtypes. Consequently, personalized oncology enhances therapeutic efficacy while minimizing unnecessary toxicity by avoiding treatments that are unlikely to benefit individual patients (28, 17). By prioritizing the molecular drivers of tumor behavior, this paradigm facilitates more informed decision-making and allows for dynamic adjustments in treatment protocols over time. Although traditional oncology has historically depended on histopathological classification, personalized medicine increasingly relies on multi-omics integration including genomics, proteomics, and transcriptomics to elucidate the complex biology of the disease (42, 21). Ultimately, the goal of this personalized approach is to improve patient survival and quality of life by tailoring therapeutic interventions to the specific biological characteristics of the disease (65, 62). Although personalized oncology holds significant promise, its clinical implementation is hindered by various practical and operational barriers that require resolution to maximize its therapeutic benefits (53, 29). Tumor heterogeneity, both within an individual tumor and between patients, complicates the identification of reliable biomarkers and predictive signatures, often leading to variable responses to targeted therapies (16, 36). Furthermore, ethical dilemmas concerning genetic testing, data security, and the fair distribution of advanced diagnostic and therapeutic tools significantly shape the adoption of these technologies in varied clinical environment (53, 29). In addition, high costs associated with comprehensive genomic profiling and targeted agents can limit availability, particularly in low-resource environments, reinforcing disparities in cancer care outcomes (11, 61). Another core challenge lies in integrating multi-disciplinary expertise and complex bioinformatic analyses into routine clinical workflows, requiring specialized infrastructure and trained personnel (9, 27).

Furthermore, while molecular tumor boards and decision-support systems can help interpret genomic data, standardized guidelines for translating molecular insights into actionable treatment recommendations are still evolving (15, 54). Addressing these obstacles will be critical to extending the benefits of personalized medicine beyond specialized centers and harmonizing precision oncology with broader healthcare delivery. Continued research efforts, collaborative networks, and policy frameworks are essential to support equitable, evidence-based implementation of personalized cancer care (54, 63).

Overview of Artificial Intelligence in Healthcare

The evolution of artificial intelligence (AI) in healthcare has swiftly progressed from theoretical exploration to a pivotal, transformative paradigm, fundamentally altering clinical operations and patient care outcomes (17). Central to this advancement is the synthesis of machine learning (ML), deep learning (DL), and natural language processing (NLP) techniques, which enable the extraction of subtle, non-obvious patterns from complex biomedical datasets that exceed human analytical capabilities (6). These computational approaches have demonstrated considerable success in diagnostic imaging, including the detection of pathological features in radiographs, MRI, and CT scans, leading to enhanced accuracy and reduced time to diagnosis compared to traditional methods (22). Beyond imaging, AI systems contribute to predictive analytics for disease progression, automated triage, and real-time monitoring of patient health, thereby facilitating proactive care strategies. Crucially, AI-driven decision support tools are capable of synthesizing diverse clinical inputs including electronic health records (EHRs), genomic profiles, and real-time biometric metrics to generate precision therapeutic strategies tailored to individual patient vulnerabilities (15). Although the capacity of intelligent systems to accelerate clinical operations and optimize resource distribution is well-documented, significant hurdles regarding information confidentiality, system interoperability, and modeling inequities continue to impede widespread adoption (27). Nevertheless, as ongoing research aims to enhance algorithmic robustness and mitigate normative constraints, the widespread adoption of intelligent tools in medical practice holds the promise of substantially elevating both operational efficiency and the standard of patient care (34). A summary of key studies regarding AI applications in healthcare between 2020 and 2025 is presented in (Table 1).

The widespread adoption of AI-driven solutions in healthcare mandates a balanced approach that harmonizes technological innovation with stringent ethical oversight and clinical validation (53). A pivotal strength of artificial intelligence in modern

Table1. Key AI in Healthcare Studies (2020–2025) – Updated with Real References.

Study Title	AI Method	Data Type	Key Findings/Achievements	Advantages	Limitations	Reference
Use of Artificial Intelligence in Healthcare: A Comprehensive Review	ML & DL	Clinical, Imaging, Genomics	Broad-spectrum AI utility: from detection to therapy	Broad scope, identifies trends	General review, not disease-specific	Rob,M.(2025)
AI Applications in Healthcare: Advances in Cancer, Diabetes, and Epidemiology	2025	ML, DL	Multi-modal (clinical, imaging, lab)	Highlights AI use in cancer prediction and patient monitoring	Multi-disease applicability	Limited experimental validation
Use of Artificial Intelligence in Healthcare: A Review	2025	ML, DL	Clinical, Health Records	Discusses adoption, challenges, and future trends	Insight into real-world implementation	Broad focus, lacks quantitative metrics
Role of AI in Healthcare Settings: A Systematic Review	2025	ML Ensemble	Clinical, Lab, Imaging	Improves decision-making and workflow efficiency	Evidence-based insights	Small sample sizes in included studies
AI in the Health Sector: Skills for Future Professionals	2025	ML, NLP	Clinical, Training	Identifies key skills for healthcare professionals to work with AI	Focus on workforce readiness	Not focused on clinical outcomes
AI for Early Cancer Detection	2024	CNN + ML	Imaging (Mammography, MRI)	Enhanced diagnostic accuracy for breast and lung cancer	Early detection, improves survival rates	Requires large labeled datasets
Predictive Analytics for Patient Outcomes Using AI	2024	DL + Ensemble ML	Clinical, Lab, Multi-omics	Predicts treatment response and risk of adverse events	Supports personalized medicine	Computationally intensive

medicine is its capacity to synthesize massive, multi-source clinical datasets. This proficiency facilitates advanced prognostic analytics, which empower clinicians to forecast patient trajectories with high precision, customize therapeutic interventions based on individual profiles, and optimize prophylactic health strategies (5). For instance, AI-based tools can identify subtle trends in longitudinal health records that are associated with disease onset or progression, helping clinicians tailor interventions before symptoms escalate (19). Moreover, AI accelerates research workflows by facilitating drug discovery, optimizing clinical trial design, and enhancing molecular profiling, which collectively support the advancement of precision medicine (37). The convergence of AI with telehealth infrastructures and remote monitoring ecosystems

allows intelligent care models to transcend physical hospital boundaries, thereby extending high-quality medical support into community and home-based environments (39). However, achieving widespread clinical utility requires overcoming substantial barriers, such as ensuring algorithmic transparency, addressing inequities in data representation, and establishing standardized validation frameworks for AI applications (18). Sustained collaborative inquiry and stringent regulatory frameworks are paramount for translating the theoretical promise of artificial intelligence into tangible clinical benefits on a global scale (30).

AI Algorithms and Techniques in Breast Cancer

Artificial intelligence (AI) frameworks employ sophisticated computational methodologies to decode

complex biomedical patterns, significantly enhancing breast cancer diagnostic precision and management protocols. Traditional machine learning classifiers specifically support vector machines (SVM), random forests, and neural networks have been extensively deployed to differentiate benign from malignant tumors using clinical and imaging records, frequently surpassing conventional statistical approaches in both accuracy and computational speed (31). Within this landscape, deep learning (DL), which mimics the hierarchical information processing of the human cerebral cortex, has emerged as a dominant paradigm due to its capacity for autonomous feature extraction from raw data, thereby obviating the need for manual engineering. Notably, convolutional neural networks (CNNs) have demonstrated superior efficacy in analyzing mammographic, sonographic, and magnetic resonance imaging (MRI) scans, yielding high sensitivity and specificity in lesion detection (32). Furthermore, emerging transformer-based architectures are being investigated to synthesize multi-view and multi-scale data, improving diagnostic robustness. Hybrid models that integrate classical machine learning with deep learning, or leverage transfer learning, have also shown promise, particularly in data-scarce environments. To address the 'black-box' opacity of these models and foster clinical trust, explainable AI (XAI) frameworks, such as SHAP (Shapley Additive Explanations), are increasingly adopted to enhance model interpretability. However, concerns regarding generalizability across diverse patient populations and clinical settings persist, emphasizing the necessity for rigorous validation and standardized benchmarking of AI algorithms in oncology (15).

Recent advancements in breast cancer AI research have shifted focus from mere predictive accuracy toward clinical utility and interpretability. Transfer learning, which leverages pre-trained models for specific imaging tasks, has proven effective in mitigating the reliance on extensive labeled datasets while sustaining high diagnostic performance, particularly within convolutional frameworks like ResNet and DenseNet (45). Similarly, ensemble methods that aggregate predictions from multiple algorithms have demonstrated enhanced robustness and reduced overfitting across heterogeneous data sources. To bridge the gap between algorithmic output and clinical decision-making, explainability tools such as model-agnostic interpreters like LIME and SHAP are being adopted to clarify algorithmic logic, a prerequisite for establishing clinical trust and ethical compliance (18). Furthermore, sophisticated recurrent and transformer-based architectures are currently under investigation for processing sequential and multimodal inputs, such as longitudinal time-series data from electronic health

records, thereby extending AI capabilities beyond static image analysis. The incorporation of federated learning paradigms also facilitates collaborative model development across institutions while preserving patient privacy, thus addressing critical data governance issues (27). Despite these technical strides, rigorous validation across large, diverse clinical cohorts remains indispensable to guarantee equitable performance and mitigate bias before these systems can be safely integrated into routine clinical workflows (6).

AI in Early Detection of Breast Cancer

Improving clinical outcomes and mitigating mortality rates in breast cancer are inextricably linked to early detection, a domain where artificial intelligence has emerged as a transformative catalyst (2). Within this context, machine learning and deep learning frameworks, particularly convolutional neural networks (CNNs), have become instrumental in the analysis of mammography, ultrasound, and MRI scans, demonstrating enhanced sensitivity for early-stage malignant lesion identification compared to conventional radiological standards (38). The deployment of AI-driven triage protocols facilitates the automated flagging of suspicious regions, thereby alleviating cognitive burden on radiologists while minimizing inter-observer variability across diverse healthcare settings. Furthermore, the capacity of these systems to harmonize heterogeneous data sources such as patient histories, genetic markers, and prior imaging records enables more precise risk stratification and personalized screening intervals (66). At the population level, the integration of AI into mammography workflows has been correlated with increased detection rates of early-stage tumors and a concomitant reduction in false-positive findings, underscoring its dual contribution to both patient care quality and systemic efficiency (58). However, the generalizability of these models remains contingent upon the availability of high-quality, diverse, and large-scale training datasets, presenting a significant hurdle for widespread implementation. Overcoming challenges related to class imbalance, image artifacts, and protocol heterogeneity is essential for robust clinical deployment. Ultimately, AI is envisioned not as a replacement for radiologists, but as an adjunctive tool that augments human judgment, paving the way for a more efficient and accurate early detection paradigm (26).

Optimizing surveillance protocols and selecting supplementary imaging modalities for susceptible individuals necessitates a more precise identification of high-risk groups, a task where artificial intelligence plays a pivotal role. The field of radiomics, by leveraging quantitative data mined from medical imagery and integrating it with

intelligent algorithms, can unveil subtle textural and morphological precursors of malignancy that often precede clinically palpable lesions (38). The precision of screening recommendations is significantly augmented by synthesizing individual risk variables such as age, familial history, and hormonal status with AI-driven imaging predictions. Evidence derived from multi-institutional studies indicates that AI-based risk stratification strategies exhibit superior efficacy compared to traditional tools like the Gail or Tyrer-Cuzick calculators, particularly when applied to heterogeneous and diverse populations (19). Moreover, AI can assist in reducing disparities in breast cancer screening by standardizing image interpretation and decision-making, minimizing observer variability that often affects early detection in community clinics and low-resource settings (66). Despite these advancements, regulatory approval, ethical considerations, and clinician trust remain key factors influencing adoption in routine clinical practice (53). Continuous retraining with diverse datasets, performance monitoring, and transparent reporting of algorithmic limitations are essential for safe deployment (56).

The diagnostic scope of artificial intelligence has expanded well beyond traditional radiological modalities to encompass the analysis of genetic profiles and molecular signatures. Innovative approaches utilizing non-invasive blood-based assays, particularly those analyzing circulating tumor DNA (ctDNA) alongside other biomarkers, have demonstrated significant potential in detecting microscopic disease remnants and predicting early tumor relapse (31). Concurrently, sophisticated algorithms harnessing the convergence of genomics, transcriptomics, and proteomics are capable of unveiling hidden molecular alterations that manifest months or even years before any radiological findings become apparent. This capability lays a robust foundation for truly personalized early detection paradigms (16). Such approaches allow for longitudinal monitoring and rapid intervention, potentially improving survival outcomes. Additionally, AI models can be incorporated into mobile health platforms and telemedicine frameworks to expand screening access, particularly in underserved areas (39). Challenges remain in data harmonization, algorithm interpretability, and establishing standardized clinical thresholds, but ongoing research and prospective trials are addressing these limitations. Collectively, AI-based early detection represents a convergence of imaging, molecular diagnostics, and predictive analytics, offering a transformative potential for breast cancer management (22).

AI in Predicting Treatment Response

Precise forecasting of treatment response serves as the pivotal element in personalized breast cancer

management, enabling the alignment of therapeutic protocols with the unique biological and therapeutic profile of each patient's tumor. Recent advancements in artificial intelligence (AI) have demonstrated substantial efficacy in this domain by harnessing multi-modal data streams encompassing histopathology, clinical imaging, and molecular profiles to forecast individualized outcomes with greater reliability than conventional statistical models (47). For instance, interpretable deep learning models applied to digital whole-slide histopathological images have exhibited strong discriminative power in predicting neoadjuvant therapy responses. These models correlate predictive scores with tumor-infiltrating lymphocyte patterns and microenvironmental features, providing biologically relevant insights into treatment efficacy (10). The clinical utility of such AI-driven frameworks lies in their capacity to stratify patients based on their potential therapeutic response, thereby enabling healthcare providers to mitigate futile toxicity in unlikely responders and facilitating a more precise pivot to alternative treatment strategies. Furthermore, integrating radiomic signatures from magnetic resonance imaging (MRI) or mammography with clinical data enhances model granularity, leading to improved stratification of responders versus non-responders (48). Notwithstanding these technological strides, widespread clinical adoption of AI is still constrained by formidable obstacles, particularly regarding model interpretability, generalizability across independent cohorts, and the provision of actionable insights for medical practitioners. Overcoming these limitations is a prerequisite for transitioning predictive algorithms from research environments into integrated diagnostic workflows. Such a transition is critical to enable the precise guidance of therapeutic strategies and, consequently, the optimization of patient clinical trajectories (20).

Although artificial intelligence offers substantial promise in anticipating how breast cancer patients will respond to therapy, rigorous evaluations underscore ongoing methodological and translational barriers. Resolving these issues is a prerequisite for realizing the technology's true clinical value. A broad systematic review of existing models highlighted issues such as limited external validation, data and code unavailability, and under-reporting of demographic variables, which collectively contribute to a high risk of bias in many predictive frameworks (48). Furthermore, although deep learning and machine learning algorithms have achieved remarkable precision in retrospective studies, it is crucial to conduct prospective validations across heterogeneous patient populations. This step is necessary to verify the models' robustness and applicability in varied clinical environments.

Current research efforts also seek to optimize predictive models by incorporating tumor genomics, proteomics, and dynamic changes in longitudinal datasets, which can capture treatment response trajectories with greater fidelity (13). Explainable AI (XAI) methods are increasingly integrated into predictive systems to enhance clinician trust and facilitate interpretation of model decisions, making them more amenable to clinical adoption (18). Subsequent developments in this domain are anticipated to arise from concerted efforts aimed at harmonizing reporting standards, enhancing data interoperability, and embedding AI-generated prognoses into multidisciplinary clinical workflows. Such integration is pivotal for advancing precision medicine and delivering tailored therapeutic regimens to women diagnosed with breast cancer (28).

AI in Prognosis and Recurrence Prediction

Precision in prognostic assessment and recurrence forecasting constitutes the cornerstone of optimal breast cancer care, directly guiding the selection of adjuvant treatments and surveillance protocols. While conventional predictive frameworks predominantly utilize standard clinicopathological parameters specifically tumor dimensions, histological grading, and nodal involvement these traditional metrics frequently fall short of encapsulating the intricate biological heterogeneity that drives disease evolution (8). The integration of multi-modal data including clinical histories, radiomic features, and molecular signatures has positioned Artificial Intelligence (AI), specifically Machine Learning (ML) and Deep Learning (DL) architectures, as a pivotal tool for refining prognostic precision in breast cancer. Empirical evidence from systematic reviews indicates that algorithms such as Support Vector Machines (SVM), Random Forests (RF), and Neural Networks outperform traditional statistical methods in forecasting overall survival and recurrence risk. This superiority stems from their capacity to extract subtle, non-linear patterns from high-dimensional datasets (43). Consequently, these AI-driven frameworks facilitate the stratification of patients into distinct risk tiers, thereby empowering clinicians to tailor follow-up schedules and therapeutic aggressiveness to individual risk profiles. Nevertheless, the clinical translation of these models is currently hindered by a lack of robust external validation across heterogeneous populations, alongside variability in dataset quality and scale, which may compromise model generalizability (50). Despite these limitations, the incorporation of AI into prognostic frameworks remains a promising avenue for advancing precision oncology and enhancing outcome prediction (65).

By deciphering intricate morphological patterns in hematoxylin and eosin (H&E) stained slides that escape human detection, deep learning algorithms have significantly broadened the horizon of AI-driven prognostics. These models can extract rich predictive insights from histopathological images, correlating subtle morphological cues with recurrence risks, thereby surpassing the limitations of conventional grading systems (19). Furthermore, the synergy of radiomic signatures derived from medical imaging with genomic and clinical data has elevated predictive accuracy, enabling a more granular mapping of disease progression and the identification of high-risk individuals (12). To mitigate the risks of overfitting inherent in heterogeneous datasets, ensemble techniques that aggregate outputs from multiple machine learning models have proven effective in stabilizing risk assessments. To address the 'black box' nature of these complex models, Explainable AI (XAI) frameworks like SHAP (Shapley Additive Explanations) are increasingly utilized to enhance transparency, allowing clinicians to discern the specific features driving recurrence predictions and fostering clinical trust (10). However, the widespread adoption of these advanced tools in routine care is contingent upon resolving critical ethical issues, including data privacy, algorithmic bias, and the necessity for rigorous prospective validation (53). Ultimately, sustained algorithmic refinement and robust multi-institutional partnerships are indispensable for developing clinically actionable and reliable recurrence prediction models (54).

In the realm of advanced breast cancer, the utility of Artificial Intelligence extends well beyond merely forecasting recurrence; it now plays a pivotal role in predicting comprehensive prognostic outcomes, including long-term survival probabilities and metastatic potential. Recent scoping reviews underscore the efficacy of supervised learning frameworks specifically Random Survival Forests and Logistic Regression in estimating critical endpoints such as progression-free and overall survival. These models demonstrate promising predictive accuracy when leveraging comprehensive datasets that integrate rich clinical histories with genomic profiles, thereby offering a more holistic view of patient prognosis (59). These models not only support individualized patient counseling but also help oncologists identify candidates for more aggressive adjuvant therapies or closer monitoring. Importantly, combining multi-omics data with deep learning features has shown potential for uncovering latent prognostic biomarkers that traditional methods may overlook (36). Embedding advanced computational tools within clinical decision frameworks demands a rigorous evaluation of algorithmic transparency and clinical applicability. This is essential to

prevent healthcare professionals from placing undue trust in black-box outputs without grasping the underlying rationale. To validate the robustness and generalizability of AI-driven prognostic models across varied healthcare settings, it is imperative to conduct longitudinal studies and adhere to uniform reporting standards (49). Ongoing investigation is crucial to delineate ethical deployment strategies, thereby enhancing predictive precision and facilitating truly personalized therapeutic interventions for breast cancer patients (33).

AI in Biomarker Discovery and Molecular Profiling

Advances in artificial intelligence (AI) have revolutionized biomarker discovery and molecular profiling in breast cancer, enabling identification of novel diagnostic, prognostic, and predictive markers from high-dimensional multi-omics data (16). Advanced machine learning architectures, such as gradient boosting, support vector machines, and random forests, possess the capacity to decipher intricate molecular dynamics within multi-omics datasets (genomics, transcriptomics, and proteomics), surpassing the limitations of traditional statistical methods in identifying subtle interactions (13). Furthermore, the integration of deep learning paradigms including graph neural networks and autoencoders has significantly refined the identification of complex biomarker signatures. These deep learning models excel at modeling non-linear dependencies and high-order feature correlations, thereby offering a more nuanced understanding of biological complexity. Integration of imaging-derived radiomic features with molecular profiles allows for non-invasive prediction of tumor biology and therapy response. AI-based molecular profiling not only accelerates biomarker discovery but also facilitates stratification of patients for targeted therapies, optimizing precision oncology. However, challenges remain in ensuring data quality, harmonizing multi-center datasets, and interpreting the biological relevance of AI-identified features, which are critical for clinical translation (60). To align algorithmic outputs with biological reality, Explainable AI (XAI) is increasingly utilized to demystify clinical decision-making processes. Moving forward, research priorities lie in synthesizing longitudinal multi-omics profiles with clinical endpoints. This integration is pivotal for refining biomarker panels, ultimately enabling more precise, individualized therapeutic strategies for breast cancer patients.

AI approaches also enable identification of predictive biomarkers for therapeutic response and disease progression, supporting the development of personalized treatment strategies. Deep learning

models trained on genomic and transcriptomic datasets can detect subtle patterns associated with drug sensitivity and resistance, enabling early intervention and therapy optimization (12). Furthermore, AI-assisted network-based analyses facilitate the discovery of key regulatory genes and pathways that influence tumor aggressiveness and metastasis. The convergence of AI-driven analytics with liquid biopsy markers specifically circulating tumor DNA (ctDNA) and exosomal signatures enables a non-invasive, real-time surveillance of tumor dynamics. This integration facilitates the continuous tracking of evolving molecular profiles, thereby offering immediate clinical insights into therapeutic efficacy and patient-specific disease trajectories (31). Despite significant advances, challenges such as interpretability of complex models, validation across diverse populations, and the need for standardized reporting frameworks remain. Collaborative efforts among computational scientists, biologists, and clinicians are critical to translate AI-based biomarker discoveries into clinically actionable insights. The surge in multi-omics data and advanced computational tools positions AI as a key driver in precision oncology. This synergy is set to transform breast cancer management by refining diagnostic accuracy, enhancing prognostic stratification, and enabling truly individualized therapeutic regimens. For a comprehensive summary of key studies and methodologies in this domain, please refer to Table 2.

AI in Personalized Treatment Planning and Clinical Decision Support

To optimize personalized breast cancer management, clinical decision support systems are increasingly adopting AI technologies. By harnessing machine and deep learning algorithms, these platforms integrate multimodal patient data spanning radiology, histopathology, genomic profiles, and therapeutic history into actionable clinical intelligence for practitioner (27). AI-driven CDSS can support diagnostic decisions, recommend optimal therapy regimens, and predict patient outcomes, thereby reducing variability in clinical practice and improving adherence to evidence-based guidelines. Real-world studies demonstrate that AI integration can shorten diagnostic timelines, reduce unnecessary procedures, and provide risk stratification for complex cases, ultimately enhancing patient safety and treatment efficacy (15). Nevertheless, successful integration requires careful attention to interoperability with electronic health records (EHRs), clinician training, and regulatory compliance. Additionally, clinicians must maintain oversight, as AI outputs should complement rather than replace expert judgment. Transparency, interpretability, and validation in diverse clinical settings are critical to fostering trust

Table 2. Key Studies of AI in Biomarker Discovery and Molecular Profiling (2020–2025).

Study Title	Year	AI Method	Data Type	Key Findings / Achievements	Advantages	Limitations
AI-assisted multi-omics biomarker discovery	2024	Random Forest	Genomics, Transcriptomics	Identified 15 novel biomarkers linked to therapy response	High interpretability	Requires large datasets
Deep learning for breast cancer molecular profiling	2023	Autoencoder	Transcriptomics, Proteomics	Detected non-linear molecular interactions predictive of metastasis	Captures complex patterns	Computationally intensive
Graph neural networks in biomarker prediction	2022	GNN	Multi-omics	Mapped regulatory gene networks	Models high-order interactions	Hard to interpret
AI-based liquid biopsy biomarker detection	2023	CNN + ML	ctDN, Exosomes	Early detection of therapy resistance	Non-invasive, dynamic monitoring	Limited external validation
Radiogenomics for breast cancer profiling	2021	CNN + RF	Imaging + Genomics	Integrated imaging and molecular data for risk stratification	Multi-modal integration	Dataset heterogeneity
Explainable AI for biomarker discovery	2024	SHAP + ML	Genomics	Transparent feature importance for biomarkers	Enhances clinician trust	May miss subtle features
Ensemble ML models for predictive biomarkers	2020	Ensemble (RF + SVM)	Transcriptomics	Predicted therapy response with high accuracy	Reduces overfitting	Limited interpretability

and facilitating widespread adoption. By bridging computational predictions with clinical workflows, AI-enabled CDSS holds promise for transforming routine breast cancer management into a more precise and patient-centered practice.

Integration of AI into multidisciplinary tumor boards has shown promise in optimizing therapeutic strategies and improving decision-making consistency. By aggregating data from imaging, pathology, genomics, and patient-reported outcomes, AI models can highlight key prognostic factors and potential therapeutic targets that might otherwise be overlooked in time-constrained clinical discussions (63). In pilot implementations, AI-assisted tumor boards improved concordance with guideline-based recommendations and facilitated personalized treatment planning, particularly for complex or high-risk cases (43). Furthermore, real-time predictive analytics can flag patients at risk of adverse events or suboptimal responses,

allowing clinicians to proactively modify treatment plans. Challenges include addressing data privacy concerns, standardizing AI model outputs for diverse healthcare systems, and ensuring equitable access across institutions. Bridging the gap between algorithmic outputs and clinical practice requires synergistic efforts among data scientists, medical practitioners, and regulatory bodies. This interdisciplinary collaboration is vital for overcoming implementation hurdles and ensuring that AI-driven insights lead to tangible patient benefits. Ultimately, embedding AI within decision-support frameworks marks a paradigm shift toward precision oncology, prioritizing individualized care in breast cancer management.

The clinical implementation of AI-driven decision support systems hinges on rigorous ethical oversight and robust regulatory compliance. To guarantee patient safety and sustain practitioner trust, it is imperative to prioritize algorithmic transparency, actively mitigate

inherent biases, and establish continuous post-deployment monitoring protocols (53). Concurrently, regulatory bodies are refining frameworks to accommodate adaptive AI architectures that evolve dynamically through continuous learning from new patient cohorts. From an operational standpoint, seamless adoption requires intuitive user interfaces and deep interoperability with existing hospital IT ecosystems, particularly electronic health records (EHRs), alongside standardized reporting metrics for AI outputs (56). Early pilot data indicate that hybrid decision-making combining AI insights with clinical expertise enhances diagnostic precision, alleviates cognitive load, and fosters evidence-based practices. However, definitive validation necessitates large-scale, prospective, multi-center trials to assess model generalizability, fairness, and efficacy across diverse demographic groups. As these technologies mature, their embeddedness in clinical workflows is poised to catalyze the widespread adoption of precision medicine, thereby elevating both therapeutic outcomes and the overall standard of care for breast cancer patients.

Integration of Multi-Omics Data with AI

Synthesizing multi-omics data with artificial intelligence (AI) has become a cornerstone of precision oncology for breast cancer. While multi-omics layers spanning genomics, transcriptomics, proteomics, epigenomics, and metabolomics offer a holistic view of tumor biology, their sheer complexity and dimensionality often overwhelm conventional statistical methods (16). To address this, advanced AI paradigms, including deep learning (DL) and ensemble machine learning (ML), are employed to decipher complex molecular networks and latent interactions governing disease progression and therapeutic efficacy (42). By harmonizing these heterogeneous data streams, AI constructs detailed molecular profiles tailored to individual patients, facilitating the stratification of tumors into distinct biological subtypes. This stratification is critical for predicting differential responses to targeted interventions, thereby enabling truly personalized treatment strategies. Importantly, these integrative approaches can uncover novel biomarkers and therapeutic targets that may be missed by single-omics analyses, enhancing precision oncology initiatives. However, challenges such as data harmonization, batch effects, and standardization across platforms must be addressed to ensure reproducibility and clinical utility. Incorporating explainable AI (XAI) methods further facilitates interpretation of complex models, linking computational findings to biologically meaningful insights.

AI-driven multi-omics integration has demonstrated significant potential for predicting clinical outcomes

and treatment response in breast cancer. Models that combine genomic mutations, transcriptomic signatures, and proteomic profiles can predict therapeutic efficacy and identify patients at high risk of relapse with higher accuracy than conventional single-omics approaches (20). Radiogenomics, which integrates imaging features with multi-omics data, further enhances predictive performance by linking phenotypic tumor characteristics to underlying molecular mechanisms (38). Facilitating adaptive, individualized therapeutic regimens such as modifying interventions in response to anticipated resistance patterns or disease trajectories represents a key advantage of these methodologies. However, significant hurdles remain, notably the requirement for extensive, high-fidelity datasets and rigorous external validation across heterogeneous clinical cohorts. Furthermore, addressing ethical imperatives concerning data confidentiality, informed consent, and algorithmic interpretability is essential for successful clinical implementation. Despite these challenges, integrative multi-omics AI models are poised to transform personalized breast cancer management by providing a holistic view of tumor biology and informing precise therapeutic decisions.

Future directions in AI-powered multi-omics integration emphasize the development of dynamic, longitudinal models that capture temporal changes in tumor biology. The longitudinal integration of serial biopsy data, circulating tumor DNA (ctDNA) signatures, and proteomic profiles allows for the dynamic tracking of tumor evolution and therapeutic efficacy. This continuous monitoring yields critical, actionable intelligence that informs adaptive clinical decision-making and personalized treatment adjustments (16). Network-based AI approaches can map interactions among genes, proteins, and metabolites, uncovering key regulatory pathways that drive progression and resistance (21). Combining these computational insights with clinical decision support systems facilitates the translation of multi-omics data into practical recommendations for patient management. The enhanced interpretability and standardization of artificial intelligence algorithms are pivotal for their seamless incorporation into clinical practice. As these technological constraints are addressed, oncologists will be empowered to optimize therapeutic. Collaborative initiatives that share multi-omics datasets and establish benchmarking standards will be critical for validating these models and ensuring their equitable application across populations.

Challenges and Limitations of AI in Personalized Breast Cancer Medicine

Although artificial intelligence (AI) holds considerable potential for advancing personalized

breast cancer care, its integration into routine clinical practice faces substantial barriers. A primary hurdle is the heterogeneity and variable quality of data, given that robust AI development necessitates extensive, high-quality annotated datasets for both training and validation (29). Discrepancies across imaging techniques, genomic sequencing platforms, and clinical records can introduce systematic biases, thereby restricting the generalizability of AI models. Furthermore, the “black-box” nature of many algorithms poses a significant challenge to clinical trust; physicians are often hesitant to adopt AI-driven recommendations without clear interpretability and transparency regarding the decision-making logic (10). Regulatory frameworks also lag behind technological advancements, creating uncertainty for adaptive algorithms that evolve over time, which raises complex issues regarding safety, accountability, and ongoing validation. Additionally, unequal access to high-performance computing infrastructure and curated datasets risks widening health disparities, particularly in under-resourced healthcare systems. To ensure ethical deployment, it is imperative to address patient consent, data privacy, and algorithmic bias. Ultimately, realizing the clinical utility of AI requires standardized data governance, rigorous external validation, and robust interdisciplinary partnerships.

Another critical limitation involves model validation and reproducibility. Many AI algorithms are developed using retrospective, single-center datasets, which can limit external generalizability and lead to overfitting (25). Prospective, multi-center

studies are needed to confirm predictive performance across diverse populations and healthcare systems. Integration challenges also arise when attempting to implement AI tools into existing clinical workflows, including interoperability with electronic health records, training clinicians, and ensuring seamless data input. Computational complexity and high resource demands can further impede routine adoption, particularly in institutions with limited infrastructure. Furthermore, explainable AI (XAI) approaches are still evolving, and there is a trade-off between model complexity and interpretability. Ultimately, addressing the ethical, legal, and social dimensions such as algorithmic bias and the maintenance of patient trust requires robust governance frameworks and stringent regulatory supervision (53). Surmounting these multifaceted challenges is a prerequisite for fully unlocking the capacity of artificial intelligence to provide safe, equitable, and highly effective personalized interventions in breast oncology. For a detailed summary of these limitations and their potential impacts, please refer to Table 3.

Future Directions and Emerging Trends in AI-driven Oncology

Future Directions and Emerging Trends in AI-driven Oncology The trajectory of artificial intelligence in personalized breast oncology is shifting towards highly sophisticated multimodal integration, synthesizing multi-omics, radiological, and clinical information to maximize therapeutic efficacy. Recent breakthroughs in deep learning

Table 3. Key Challenges and Limitations of AI in Personalized Breast Cancer Medicine (2020–2025).

Challenge / Limitation	Description / Key Points	Potential Impact	Reference
Data Quality & Availability	Limited datasets, missing values, non-standardized formats hinder model training	Reduced model accuracy and generalizability	Investigating the effects... (2024)
Lack of Standardization	Diverse protocols across institutions complicate data integration	Poor reproducibility of AI models	The role of AI in enhancing breast... (2025)
Explainability / “Black Box”	Complex AI models are hard for clinicians to interpret	Reduced trust and adoption in clinical settings	Explainable AI in breast cancer... (2024)
Ethical & Legal Concerns	Bias in datasets, privacy concerns, liability issues	Risk of inequitable treatment, legal challenges	AI and Decision-Making in Oncology (2025)
Integration with Clinical Workflow	Difficulty embedding AI tools into existing hospital systems	Limits practical adoption	Challenges in implementing AI... (2025)
Regulatory & Validation Hurdles	Lack of clear regulatory guidelines for AI-based medical tools	Delays in clinical translation	Advancing cancer care through AI... (2025)
Model Generalizability	Models trained on one population may fail on others	Limited applicability across demographics	Artificial Intelligence in breast... (2025)

and graph neural networks enable the mapping of intricate biological pathways, thereby accelerating the identification of new therapeutic targets and predictive biomarkers (40). Furthermore, the seamless incorporation of longitudinal data streams such as serial tissue biopsies, circulating tumor DNA (ctDNA) analysis, and continuous monitoring via wearable sensors facilitates dynamic disease tracking and real-time treatment adaptation. To enhance clinical adoption, the emergence of Explainable AI (XAI) frameworks is expected to bolster algorithmic transparency and clinician confidence, effectively translating complex computational outputs into actionable clinical decisions. Finally, industry-wide initiatives aimed at standardizing data architectures, promoting cross-institutional data sharing, and rigorously benchmarking AI tools are poised to drive innovation while ensuring robust generalizability across diverse patient cohorts (52).

A burgeoning frontier in this domain involves the deployment of AI-driven simulations and digital twin technologies to forecast individualized therapeutic responses. By synthesizing patient-specific genomic, biological, and lifestyle parameters, digital twin constructs enable the *in silico* modeling of tumor progression and treatment efficacy, thereby allowing clinicians to virtually evaluate multiple intervention protocols prior to clinical implementation (17). Concurrently, artificial intelligence is poised to revolutionize adaptive clinical trial designs by facilitating real-time dynamic stratification and resource allocation through predictive analytics. Furthermore, the incorporation of Natural Language Processing (NLP) systems will unlock valuable information embedded within unstructured clinical documentation, pathology findings, and scientific literature, thereby augmenting structured data repositories and refining personalized care pathways. The establishment of robust ethical AI frameworks remains imperative to guarantee algorithmic transparency, reduce inherent biases, and protect patient confidentiality within these sophisticated applications (53). Collectively, these advancements herald a paradigm shift toward proactive, patient-centric oncology, promising to significantly elevate the precision, operational efficiency, and equity of breast cancer management.

The integration of artificial intelligence with multi-omics and clinical informatics marks a pivotal transition toward a unified global framework for oncology research and practice. By leveraging federated learning architectures and robust privacy-preserving data-sharing mechanisms, researchers can now circumvent data silos and address confidentiality concerns without compromising patient anonymity, thereby mitigating issues related to data scarcity (27). When embedded within clinical decision

support systems (CDSS), these advanced algorithms facilitate real-time analytical capabilities, enabling predictive modeling for therapeutic efficacy, disease recurrence, and adverse drug reactions. Such capabilities empower clinicians to adopt proactive rather than reactive intervention strategies. To ensure the safe and equitable implementation of these technologies, sustained investment in clinician education and the establishment of comprehensive regulatory guidelines are imperative. Ultimately, this technological convergence is projected to accelerate the trajectory of precision oncology, particularly for breast cancer management, by delivering personalized therapeutic regimens that improve clinical outcomes and narrow healthcare disparities on a global scale (55). As these innovations mature, AI-driven oncology is poised to fundamentally shift the medical paradigm from reactive treatment to a comprehensive model of predictive, preventive, and proactive care.

DISCUSSION

Despite the transformative potential of artificial intelligence (AI) in personalizing breast cancer care, its widespread clinical integration faces significant hurdles related to data generalizability and model interpretability. The majority of current AI frameworks are constrained by their reliance on retrospective, single-institution datasets, which restricts their external validity and hinders seamless translation into routine clinical practice. Furthermore, the “black-box” nature of complex deep learning architectures often impedes clinician adoption due to concerns regarding algorithmic bias, data heterogeneity, and the lack of standardized validation protocols. To overcome these limitations, emerging strategies emphasize the fusion of multi-omics profiles with clinical metadata, enabling a more granular characterization of tumor heterogeneity and individualized risk stratification. Concurrently, AI-driven imaging modalities, particularly those leveraging deep learning, have demonstrated superior efficacy in early detection compared to traditional methods, effectively minimizing inter-observer variability. Moreover, predictive analytics for therapeutic response and disease recurrence hold promise for optimizing treatment regimens and mitigating overtreatment. While Explainable AI (XAI) initiatives are beginning to address transparency issues, further refinement is necessary to establish trust. Consequently, realizing the full clinical utility of AI in breast oncology demands rigorous prospective validation studies and robust integration into real-world healthcare workflows, ensuring that personalized interventions are both accurate and actionable.

CONCLUSION

Artificial intelligence represents a transformative tool for advancing personalized breast cancer medicine by enabling more precise diagnosis, improved prediction of treatment response, and enhanced prognostic assessment. Evidence indicates that AI-driven multi-modal and multi-omics models can capture complex biological patterns that traditional methods fail to identify. Despite these advances, widespread clinical adoption is constrained by methodological limitations, lack of external validation, and ethical and regulatory challenges. Addressing data standardization, transparency, and equity in model development is critical to ensure safe and effective deployment. The translational success of artificial intelligence in breast oncology hinges on the execution of rigorous prospective, multi-center trials to establish robust generalizability. Concurrently, the development of interpretable, trustworthy algorithmic frameworks and their seamless integration into clinical decision support systems are paramount for fostering clinician adoption. Ultimately, through responsible implementation and sustained interdisciplinary collaboration, AI is poised to catalyze a fundamental paradigm shift from reactive treatment modalities to a proactive, predictive, and patient-centric ecosystem of care.

REFERENCE

1. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. *Nat Med.* 2019;25(1):24-29
2. Geraerts I, De Craene B, Van Calster B, et al. Performance of artificial intelligence for detecting breast cancer on mammography: a systematic review and meta-analysis. *Lancet Digit Health.* 2023;5(3):e158-e169.
3. Bhujade PR, Ghode KR, Hatwar PR. Breast Cancer: A Comprehensive Review of Epidemiology, Risk Factors, Diagnosis and Treatment. *Int. J. Pharm. Sci. Rev. Res.* 2025.
4. Carriero A, Groenhoff L, Vologina E, Basile P, Albera M. Deep Learning in Breast Cancer Imaging: State of the Art and Recent Advancements in Early 2024. *Diagnostics.* 2024;14(8):848.
5. Chen Y, Wang F, Li H. Predictive analytics for patient outcomes using AI in healthcare. *J Health Inform Res.* 2024;8(3):215-30
6. Liu Y, Chen PH, Krause J, Peng L. How artificial intelligence will change medicine: a focus on breast cancer. *Lancet Digit Health.* 2022;4(8):e555-e567.
7. European Society of Radiology (ESR). Artificial intelligence in healthcare: Clinical applications and future perspectives. *Eur Radiol Exp.* 2024;8(1):15.
8. Freihat O, Sipos D, Kovacs A. Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. *Frontiers in Public Health.* 2025.
9. Gazquez-Garcia J, Sánchez-Bocanegra CL, Sevillano JL. AI in the health sector: Systematic review of key skills for future health professionals. *JMIR Medical Education.* 2025;11:e58161.
10. Ghasemi A, Hashtarkhani S, Schwartz DL, Shaban-Nejad A. Explainable artificial intelligence in breast cancer detection and risk prediction: A systematic scoping review. *NPJ Digit Med.* 2024;7:45.
11. Giger ML. Artificial intelligence in radiology: Current status and future perspectives. *Radiology.* 2024;310(2):e232100.
12. Golestan A, Tahmasebi A, Maghsoodi N, et al. Unveiling promising breast cancer biomarkers: An integrative approach combining bioinformatics analysis and experimental verification. *BMC Cancer.* 2024;24:155.
13. Hashemi S, Ghaffari P, Shaban-Nejad A. Artificial intelligence in biomarker discovery for breast cancer: Current trends and perspectives. *Briefings in Bioinformatics.* 2024;25(3):bbac642.
14. Kumar R, Singh A. Innovative approaches to EMT-related biomarker identification in breast cancer. *Biotechnol Rep.* 2025;45:e00987.
15. Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in clinical decision support for oncology: Current applications and challenges. *NPJ Digital Medicine.* 2023;6:41.
16. Kaur H, Sharma R. Longitudinal multi-omics integration for precision oncology in breast cancer. *Cancers.* 2024;16(2):457.
17. Kaur H, Sharma R, Gupta P. AI and digital twin applications in personalized oncology: Emerging trends. *Cancers.* 2024;16(4):789.
18. Kim S, Park J, Lee H. Explainable AI in clinical decision support: Current trends. *Artificial Intelligence in Medicine.* 2025;130:102345.
19. Lee G, Lee J, Kwak T-Y, et al. Predicting the risk of early-stage breast cancer recurrence using H&E-stained tissue images. *IEEE J Biomed Health Inform.* 2024;28(5):2890-9.
20. Li F, Zhou Q, Wang T. Future perspectives of AI in breast cancer precision medicine. *Bioinformatics.* 2023;39(22):btad765.
21. Li F, Zhou Q, Wang T. Network-based AI models for integrative multi-omics cancer analysis. *Bioinformatics.* 2023;39(15):btad284.
22. Arora A, Kaur J, Singh G, et al. Artificial intelligence in breast cancer diagnosis and treatment: A comprehensive review. *Cureus.* 2023;15(8):e43658.
23. Liu Y, Chen PH, Krause J, Peng L. How artificial intelligence will change medicine: A focus on breast cancer. *The Lancet Digital Health.* 2022;4(8):e555-

- 67.
24. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.
25. Zheng L, et al. A state-of-the-art review of artificial intelligence (AI) applications in healthcare. *Computers*. 2025;14(4):143.
26. Yala A, Mikhael PG, Barzilay R. Radiomics and AI in early detection of breast cancer: Emerging trends and challenges. *Radiol Artif Intell*. 2024;6(3):e230045.
27. Patel R, Singh V, Gupta P. Integration of AI in electronic health records systems: Opportunities and challenges. *Journal of Biomedical Informatics*. 2023;136:104179.
28. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. *BMJ*. 2015;350:g7594.
29. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med*. 2019;380(14):1347-58.
30. Carriero A, Groenhoff L, Vologina E, Basile P, Albera M. Deep Learning in Breast Cancer Imaging: State of the Art and Recent Advancements in Early 2024. *Diagnostics*. 2024;14(8):848.
31. Sirintrapun SJ, O'Malley DM. Liquid biopsy and AI for early breast cancer detection: Emerging clinical applications. *Journal of Clinical Oncology: Precision Oncology*. 2024;8(5):e22056.
32. Smith A, Brown L, Johnson K. AI for early cancer detection: Imaging-based approaches. *Frontiers in Oncology*. 2024;14:102345.
33. Topol EJ. Deep medicine: How artificial intelligence can make healthcare human again. *Nat Med*. 2019;25(1):34-7.
34. Ullah W, Ali Q. Role of artificial intelligence in healthcare settings: A systematic review. *Journal of Medical Artificial Intelligence*. 2025;8:24.
35. Wang Y, Li X. Integrative multi-omics analysis in breast cancer using machine learning approaches. *Frontiers in Genetics*. 2023;14:1205643.
36. Xiong X, Wang X, Liu CC, et al. Deciphering breast cancer dynamics: Insights from single-cell and spatial profiling in the multi-omics era. *Biomarker Research*. 2024;12:107.
37. Yagin G, Gormez S, Al-Hashem F, Ahmad A, Ardigò G. Biomarker discovery and development of prognostic prediction model using metabolomic panel in breast cancer patients: A hybrid methodology integrating machine learning and explainable artificial intelligence. *Frontiers in Molecular Biosciences*. 2024.
38. Yala A, Mikhael PG, Barzilay R. Radiomics and AI in early detection of breast cancer: Emerging trends and challenges. *Radiology: Artificial Intelligence*. 2024;6(3):e230045.
39. Zhang H, Chen J, Zhou Q. AI in telemedicine for remote oncology guidance. *Telemedicine and e-Health*. 2020;26(12):1500-9.
40. Zhang H, Chen J, Zhou Q. Deep learning models for integrative multi-omics in cancer research. *Briefings in Bioinformatics*. 2022;23(5):bbac237.
41. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44-56.
42. Zhou Q, Zhang H, Li F. Integrative multi-omics analysis using AI for molecular profiling in breast cancer. *Frontiers in Oncology*. 2023;13:1145697.
43. Geras KJ, Wu F, Chen Y, et al. Artificial intelligence in breast cancer imaging: A review of current applications and future directions. *Radiol Artif Intell*. 2024;6(2):e230112.
44. Liu Y, Chen PH, Krause J, Peng L. How artificial intelligence will change medicine: A focus on breast cancer. *Lancet Digit Health*. 2022;4(8):e555-67.
45. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. *Nat Med*. 2019;25(1):24-29.
46. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. *Nat Rev Cancer*. 2018;18(8):500-10.
47. McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. *Nature*. 2020;577(7788):89-94.
48. Hoffer AJ, Bhatt S, Patel PD, et al. Artificial intelligence in oncology: current applications and future perspectives. *JCO Clin Cancer Inform*. 2022;6:e2200012.
49. Liu X, Faiz SM, Garrido O, et al. Explainable artificial intelligence for healthcare. *Nat Mach Intell*. 2021;3(10):826-7.
50. Shen L, Liang S, Chen J, et al. Artificial intelligence in breast cancer survival prediction: a comprehensive systematic review and meta-analysis. *BMC Cancer*. 2023;23(1):123.
51. Topol EJ. Deep medicine: How artificial intelligence can make healthcare human again. *Nat Med*. 2019;25(1):34-7.
52. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med*. 2019;380(14):1347-58.
53. Topol EJ. Artificial intelligence in healthcare: the present and the future. *NPJ Digit Med*. 2019;2:1-10.
54. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making*. M
55. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med*. 2019;380(14):1347-58.
56. Bitencourt AGV, Thuler LCS, do Nascimento BL, de Aguiar PC. Challenges in implementing artificial intelligence in breast cancer screening programs: Systematic review and framework for safe adoption. *JMIR Med Inform*. 2023;11:e45678.

57. Geras KJ, Wu F, Chen Y, et al. Artificial intelligence's impact on breast cancer pathology: a literature review. *Diagn Pathol.* 2024;19(1):45.
58. Nature Medicine. International evaluation of an AI system for breast cancer screening. *Nat Med.* 2024;30(4):650-8.
59. McKinney SM, Sieniek M, Godbole V, et al. International evaluation of an AI system for breast cancer screening. *Nature.*
60. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. *Nat Rev Cancer.* 2018;18(8):500-10.
61. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA Cancer J Clin.* 2023;73(1):17-48.
62. World Journal of Clinical Oncology. Personalized medicine: Clinical oncology on molecular view of treatment. 2024.
63. Journal of Clinical Oncology Reviews. Precision oncology: Transforming cancer care through personalized medicine. 2025.
64. Sirintrapun SJ, O'Malley DM. Liquid biopsy and AI for early breast cancer detection: Emerging clinical applications. *JCO Precis Oncol.* 2024;8:e22056
65. BMC Cancer. Investigating the effects of artificial intelligence on the personalization of breast cancer management: a systematic study. *BMC Cancer.* 2024;24:852.
66. Journal of Clinical Medicine. Promoting Artificial Intelligence for Global Breast Cancer Risk Prediction and Screening in Adult Women: A Scoping Review. *J Clin Med.* 2024;13(9):2525.
67. Diagnostic Pathology. Artificial intelligence's impact on breast cancer pathology: a literature review. *Diagn Pathol.* 2024;19:38.
68. Geras KJ, Wu F, Chen Y, et al. Artificial intelligence in breast cancer imaging: A review of current applications and future directions. *Radiol Artif Intell.* 2024;6(2):e230112.